Lv4
500 积分 2024-10-01 加入
Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02):
3天前
已完结
Theory and practice of Bayesian and frequentist frameworks for network meta-analysis
3天前
已完结
Prognostic utility of circulating tumor DNA in classical hodgkin lymphoma: A systematic review and individual participant data bayesian meta-analysis
3天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
3天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
9天前
已完结
The oncology market for antibody–drug conjugates
9天前
已完结
Antibody–drug conjugates come of age in oncology
9天前
已完结
Optimizing treatment for HER2-positive HR-positive breast cancer
9天前
已完结
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
9天前
已完结
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
12天前
已完结
皖公网安备34019202002308
